Zevra Therapeutics (ZVRA) Net Margin (2019 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Net Margin came in at 104.61% in Q1 2026, up 11980.0% YoY from N/an in Q1 2025, and up 193.84% on a QoQ basis from 35.6% in Q4 2025.
Zevra Therapeutics (ZVRA) Net Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 8 years of Net Margin data on file, last reported at 104.61% in Q1 2026.
- Quarterly Net Margin rose 11980.0% year-over-year to 104.61% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 101.54% (up 32863.0% YoY) and the FY2025 annual result came in at 78.17%, up 52502.0% from the prior year.
- Net Margin climbed to 104.61% in Q1 2026, from 35.6% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 288.66% in Q2 2025 to a low of 1920.29% in Q2 2022.
- A 5-year average of 327.7% and a median of 269.01% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin sank 183106 bps — and 2023, when it jumped 188991 bps.
- Tracing ZVRA's Net Margin over 5 years: stood at 446.14% in 2022, then soared by 65 bps to 153.96% in 2023, then plunged by 93 bps to 297.53% in 2024, then surged by 112 bps to 35.6% in 2025, then jumped by 194 bps to 104.61% in 2026.
- The last three Net Margin figures came in at 104.61% (Q1 2026), 35.6% (Q4 2025), and 2.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 22.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.05% |
| Mar 31, 2026 | 104.61% |
| Dec 31, 2025 | 35.60% |
| Sep 30, 2025 | -2.09% |
| Jun 30, 2025 | 288.66% |
| Mar 31, 2025 | -15.19% |
| Dec 31, 2024 | -297.53% |
| Sep 30, 2024 | -899.19% |
| Jun 30, 2024 | -452.84% |
| Mar 31, 2024 | -485.31% |
| Dec 31, 2023 | -153.96% |
| Sep 30, 2023 | -358.10% |
| Jun 30, 2023 | -30.38% |
| Mar 31, 2023 | -370.50% |
| Dec 31, 2022 | -446.14% |
| Sep 30, 2022 | -240.49% |
| Jun 30, 2022 | -1,920.29% |
| Dec 31, 2021 | -104.69% |
| Sep 30, 2021 | -89.52% |
| Jun 30, 2021 | -89.23% |